DAX22.163 -1,3%ESt505.248 -1,6%Top 10 Crypto11,78 -1,9%Dow42.002 +1,0%Nas17.299 -0,1%Bitcoin76.232 +0,2%Euro1,0818 ±-0,0%Öl74,74 +1,9%Gold3.124 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Tesla A1CX3T Rheinmetall 703000 NVIDIA 918422 RENK RENK73 Lufthansa 823212 Mercedes-Benz Group (ex Daimler) 710000 BASF BASF11 HENSOLDT HAG000 Volkswagen (VW) vz. 766403 thyssenkrupp 750000 Novo Nordisk A3EU6F Amazon 906866 Siemens Energy ENER6Y BYD A0M4W9 Deutsche Telekom 555750
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Trump-Zölle im Fokus: DAX schließt in Rot -- US-Börsen schließen uneinheitlich -- BYD stärkt Europa-Vertrieb -- Chip-Aktien brechen ein -- HENSOLDT, Tesla, Microsoft, RWE, CANCOM im Fokus
Top News
Börse New York in Grün: S&P 500 zum Handelsende im Aufwind Börse New York in Grün: S&P 500 zum Handelsende im Aufwind
Zuversicht in New York: Dow Jones zum Handelsende im Plus Zuversicht in New York: Dow Jones zum Handelsende im Plus
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Dividendensaison 2025: Welche Unternehmen überraschen positiv und welche enttäuschen? Das erwartet Anleger. Jetzt mehr erfahren!

Ampliphi Biosciences Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
1,30 EUR -0,21 EUR -13,91 %
STU
1,52 USD -0,19 USD -11,11 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.52,80 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2PKLC

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS04216R1023

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolARMP

Ampliphi Biosciences Aktien News

DatumMeistgelesen
PR NewswireArmata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update
PR NewswireArmata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva
PR NewswireArmata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit
Wer­bungAmpliphi Biosciences-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireArmata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa...
PR NewswireArmata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting
PR NewswireArmata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update
PR NewswireArmata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia
PR NewswireArmata Pharmaceuticals Announces Structural Biology Publication
PR NewswireArmata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
PR NewswireArmata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium
PR NewswireArmata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer
PR NewswireArmata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update
PR NewswireArmata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
PR NewswireArmata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa ...
PR NewswireArmata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024
PR NewswireArmata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update
PR NewswireArmata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update
PR NewswireArmata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
PR NewswireArmata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit
PR NewswireArmata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update
PR NewswireArmata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference
PR NewswireArmata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023
PR NewswireArmata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus
PR NewswireArmata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
PR NewswireArmata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update
PR NewswireArmata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics
PR NewswireArmata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy
PR NewswireArmata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update
PR NewswireArmata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update
PR NewswireArmata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis
PR NewswireArmata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC
PR NewswireArmata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
PR NewswireArmata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage
PR NewswireArmata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update
PR NewswireArmata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update
PR NewswireArmata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections
PR NewswireArmata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus
PR NewswireArmata Pharmaceuticals Announces First Quarter 2022 Results and Provides Corporate Update
PR NewswireArmata Pharmaceuticals Announces Closing of Second and Final Tranche of $45 Million Private Placement with Innoviva
Wer­bung

Ampliphi Biosciences News

Ampliphi Biosciences News: auf dieser Seite finden Sie alle Ampliphi Biosciences News und Nachrichten zur Ampliphi Biosciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Ampliphi Biosciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Ampliphi Biosciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.